Helixor P (Liquid Extract From Viscum Album Subsp. Austriacum Var Pinus Sylvestris (1:20), Extraction Solvents:)

Helixor P is used as an adjunctive therapy in oncology, primarily to support patients undergoing conventional cancer treatments and to address therapy‑related symptoms.

• As an adjunct to chemotherapy, radiotherapy, or surgery for various solid tumors.
• To help alleviate treatment‑related fatigue, weight loss, and reduced appetite.
• For potential enhancement of immune response during cancer therapy.
• As part of supportive care aimed at improving patients’ quality of life.
• In palliative settings where disease control is limited but symptom management is needed.

Side‑effect profiles for Helixor P reflect its biologically active mistletoe constituents and are reported from clinical observations; most reactions are mild and reversible, while rare serious events require medical attention.

Common

• Mild injection‑site reactions such as redness, swelling, or tenderness.
• Transient flu‑like symptoms including fever, chills, or headache.
• Temporary increase in heart rate or mild hypertension.
• Nausea or mild gastrointestinal discomfort.
• Local skin irritation or pruritus at injection site.

Serious

• Allergic reactions ranging from urticaria to anaphylaxis.
• Significant hypotension or cardiovascular instability.
• Hepatic enzyme elevations indicating liver stress.
• Severe leukopenia or neutropenia observed in rare cases.

When prescribing Helixor P, clinicians should evaluate patient history and monitor for specific safety considerations.

• Contraindicated in patients with known hypersensitivity to mistletoe extracts.
• Use caution in individuals with autoimmune disorders or chronic inflammatory conditions.
• Not recommended during pregnancy or lactation due to insufficient safety data.
• Baseline and periodic assessment of blood pressure and heart rate is advisable.
• Monitor liver function tests during prolonged therapy.
• Evaluate for potential interactions with immunosuppressive agents.
• Adjust dosage or discontinue if severe adverse reactions occur.

Helixor P may influence the activity of certain medications; awareness of possible interactions helps ensure safe combined use.

Avoid

• Concurrent use with high‑dose immunosuppressants such as cyclosporine or tacrolimus.

Use with caution

• Combination with chemotherapy agents; monitor for enhanced toxicity.
• Concurrent administration of anticoagulants; observe for changes in bleeding risk.
• Use with other herbal preparations that affect immune function.
• Co‑administration with beta‑blockers; watch for additive cardiovascular effects.
• Concomitant use with vaccines; assess timing to avoid immune interference.